Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

FDA approves initiation of Progen's phase I trial in Australia for PI-88

July 6, 1999

EntreMed extends angiogenesis research agreement with Children's Hospital of Boston

July 6, 1999

Alsterpaullone is a potent CDK1/cyclin B inhibitor and antitumor agent

July 5, 1999

Onyvax and Erasmus University reach prostate cancer agreement

July 5, 1999

The Liposome Company seeks approval for Evacet in the E.U.

July 2, 1999

NA-22598B1 and B2: novel anticancer compounds produced by Streptomyces

July 2, 1999

CRC selects water-soluble paclitaxel for phase I trial

July 2, 1999

CDK4-specific antisense oligodeoxynucleotides for inhibition of tumors

July 1, 1999

Coulter, SmithKline Beecham file BLA for Bexxar

July 1, 1999

5-Halo- or nitrate-substituted paclitaxels under study at Bristol-Myers Squibb

July 1, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...